Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose-ranging study of ULTOMIRIS (Ravulizumab) in the patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Next Previous
X
Search
Trial Profile

Dose-ranging study of ULTOMIRIS (Ravulizumab) in the patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Thrombotic microangiopathy
  • Focus Therapeutic Use
  • Sponsors Alexion AstraZeneca Rare Disease

    • Most Recent Events

    • 21 Jul 2021 According to an AstraZeneca media release, the company has acquired Alexion Pharmaceuticals and subsequently changed its name to Alexion Astrazeneca Rare Disease.
    • 04 Aug 2020 New trial record
    • 30 Jul 2020 According to an Alexion Pharmaceuticals media release, the company plans to initiate limited dose-ranging studies of ULTOMIRIS in HSCT-TMA in the second half of 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top